Literature DB >> 17699173

Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy.

Anna Woo1, Daniel Monakier, Louise Harris, Ann Hill, Prasad Shah, E Douglas Wigle, Harry Rakowski, Evelyn Rozenblyum, Douglas A Cameron.   

Abstract

OBJECTIVES: To identify the determinants of appropriate and inappropriate implantable cardioverter-defibrillator (ICD) discharges in patients with hypertrophic cardiomyopathy (HCM).
DESIGN: Retrospective cohort study.
SETTING: ICD clinic at an academic hospital. PATIENTS: 61 patients with HCM who received ICDs for the primary or secondary prevention of sudden cardiac death (SCD). OUTCOME MEASURES: (a) Analysis of appropriate and inappropriate ICD discharges; (b) predictors of ICD discharges.
RESULTS: Mean (SD) age at ICD insertion was 46 (18) years (range 10-79). Follow-up time was 40 (27) months (range 7-151). Eight patients experienced an appropriate discharge, occurring 24.5 (13.6) months after ICD insertion. Appropriate ICD intervention was more common in the secondary (36%) than the primary (8%) prevention group (p = 0.02). Inappropriate ICD discharges occurred in 20 (33%) patients. Multivariate Cox regression analysis identified two significant predictors of inappropriate ICD discharges: (a) age <30 years at the time of ICD insertion (hazard ratio (HR) = 3.0 (95% CI 1.1 to 8.0; p = 0.03) and (b) history of atrial fibrillation (HR = 3.1 (95% CI 1.2 to 8.1; p = 0.02).
CONCLUSIONS: ICDs are effective in the prevention of SCD in HCM. However, there is a high incidence of inappropriate ICD discharges.

Entities:  

Mesh:

Year:  2007        PMID: 17699173      PMCID: PMC1955000          DOI: 10.1136/hrt.2006.090290

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  5 in total

Review 1.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines.

Authors:  Barry J Maron; William J McKenna; Gordon K Danielson; Lukas J Kappenberger; Horst J Kuhn; Christine E Seidman; Pravin M Shah; William H Spencer; Paolo Spirito; Folkert J Ten Cate; E Douglas Wigle
Journal:  J Am Coll Cardiol       Date:  2003-11-05       Impact factor: 24.094

2.  Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.

Authors:  B J Maron; W K Shen; M S Link; A E Epstein; A K Almquist; J P Daubert; G H Bardy; S Favale; R F Rea; G Boriani; N A Estes; P Spirito
Journal:  N Engl J Med       Date:  2000-02-10       Impact factor: 91.245

3.  High incidence of appropriate and inappropriate ICD therapies in children and adolescents with implantable cardioverter defibrillator.

Authors:  Thomas Korte; Harald Köditz; Michael Niehaus; Thomas Paul; Jürgen Tebbenjohanns
Journal:  Pacing Clin Electrophysiol       Date:  2004-07       Impact factor: 1.976

4.  Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy.

Authors:  David A Begley; Saidi A Mohiddin; Dorothy Tripodi; Judith B Winkler; Lameh Fananapazir
Journal:  Pacing Clin Electrophysiol       Date:  2003-09       Impact factor: 1.976

5.  Is inappropriate implantable defibrillator shock therapy predictable?

Authors:  Kumaraswamy Nanthakumar; Paul Dorian; Miney Paquette; Mary Greene; Janet Edwards; Denis Heng; James Noble; David Newman
Journal:  J Interv Card Electrophysiol       Date:  2003-06       Impact factor: 1.900

  5 in total
  7 in total

1.  Global longitudinal strain and left atrial volume index improve prediction of appropriate implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy patients.

Authors:  Philippe Debonnaire; Joep Thijssen; Darryl P Leong; Emer Joyce; Spyridon Katsanos; Georgette E Hoogslag; Martin J Schalij; Douwe E Atsma; Jeroen J Bax; Victoria Delgado; Nina Ajmone Marsan
Journal:  Int J Cardiovasc Imaging       Date:  2014-02-06       Impact factor: 2.357

2.  Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy.

Authors:  Martin S Maron; Ethan J Rowin; Benjamin S Wessler; Paula J Mooney; Amber Fatima; Parth Patel; Benjamin C Koethe; Mikhail Romashko; Mark S Link; Barry J Maron
Journal:  JAMA Cardiol       Date:  2019-07-01       Impact factor: 14.676

3.  Long-term follow-up of children and adolescents diagnosed with hypertrophic cardiomyopathy: risk factors for adverse arrhythmic events.

Authors:  Jeffrey P Moak; Eric S Leifer; Dorothy Tripodi; Saidi A Mohiddin; Lameh Fananapazir
Journal:  Pediatr Cardiol       Date:  2011-04-13       Impact factor: 1.655

Review 4.  Implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of outcomes and complications.

Authors:  Nelson Wang; Ashleigh Xie; Richard Tjahjono; David H Tian; Steven Phan; Tristan D Yan; Pietro Bajona; Kevin Phan
Journal:  Ann Cardiothorac Surg       Date:  2017-07

Review 5.  A primer on arrhythmias in patients with hypertrophic cardiomyopathy.

Authors:  Katy E Bockstall; Mark S Link
Journal:  Curr Cardiol Rep       Date:  2012-10       Impact factor: 2.931

Review 6.  Sudden death in hypertrophic cardiomyopathy.

Authors:  Barry J Maron
Journal:  J Cardiovasc Transl Res       Date:  2009-11-13       Impact factor: 4.132

7.  Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice.

Authors:  Franz Baudenbacher; Tilmann Schober; Jose Renato Pinto; Veniamin Y Sidorov; Fredrick Hilliard; R John Solaro; James D Potter; Björn C Knollmann
Journal:  J Clin Invest       Date:  2008-11-20       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.